ACT-078573

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2014
02420072014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
To examine the role of orexin-1 and orexin-2 receptor activity on ethanol self-administration, compounds that differentially… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Cannabinoid CB1 and orexin OX1 receptors have been suggested to form heterodimers and oligomers. Aimed at studying these… (More)
Is this relevant?
2012
2012
In this work the pharmacology and the receptor kinetics of the following orexin receptor antagonists SB-649868, ACT-078573, JNJ… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Review
2010
Review
2010
Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in… (More)
Is this relevant?
2007
2007
Brisbare-Roch et al. reply: We agree with Tafti that animal and human orexin deficiency syndromes suggest a theoretical risk of… (More)
  • table 1
Is this relevant?
Review
2007
Review
2007
10.1038/nrd2277 The sleep–wake cycle in mammals is tightly regulated by the levels of orexins, a family of two hypothalamic… (More)
Is this relevant?
2007
2007
A newly identified compound selectively blocks receptors for the protein that narcoleptics lack. The drug has the apparent… (More)
Is this relevant?
2007
2007
The sleep–wake cycle in mammals is tightly regulated by the levels of orexins, a family of two hypothalamic peptides. During… (More)
Is this relevant?